Science Explorer Back to mapMap
Discussion
Institution · Teva Pharmaceuticals (Australia)

Most cited papers from Teva Pharmaceuticals (Australia)

Teva Pharmaceuticals (Australia)

What are the most cited papers from Teva Pharmaceuticals (Australia)?

The most cited paper from Teva Pharmaceuticals (Australia) is "Chemerin Is Associated with Metabolic Syndrome Phenotypes in a Mexican-American Population" (Kiymet Bozaoglu, David H. Segal, Katherine A. Shields et al., 2009), with 262 citations. Next come "Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers" (159) and "BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria" (143).

Showing 50 of 83 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Chemerin Is Associated with Metabolic Syndrome Phenotypes in a Mexican-American Population Kiymet Bozaoglu, David H. Segal, Katherine A. Shields et al. · The Journal of Clinical Endocrinology & Metabolism Open access 27 May 2009 262
2 Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers C. Glenn Begley et al. · Science Translational Medicine Open access 22 Sep 2021 159
3 BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria Susan Branford, John Francis Seymour, Andrew Grigg et al. · Clinical Cancer Research Dec 2007 143
4 Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes Imogen Moran, Akira Nguyen, Weng Hua Khoo et al. · Nature Communications Open access 16 Aug 2018 119
5 The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study Jennifer Arnold, Caroline M. Markey, Nicol Kurstjens et al. · BMC Ophthalmology Open access 23 Mar 2016 101
6 Persistence with antihypertensive medication: Australia‐wide experience, 2004–2006 Leon A. Simons, Michael S. Ortiz, Gordon Calcino · The Medical Journal of Australia Feb 2008 73
7 Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging May Lin Yap, James D. McFadyen, Xiaowei Wang et al. · Theranostics Open access 2017 60
8 Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity Sarah L. Pogue, Tetsuya Taura, Mingying Bi et al. · PLoS ONE Open access 9 Sep 2016 60
9 An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease Adam W. Clarke, Lynn D. Poulton, Doris Shim et al. · mAbs Open access 13 Feb 2018 59
10 Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers Kelly Makarounas‐Kirchmann, Sophie Glover-Koudounas, Paolo Ferrari · Clinical Therapeutics Review Aug 2009 55
11 NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors Victoria C. Foletta, Matthew J. Prior, Nicole Stupka et al. · The Journal of Physiology Open access 10 Feb 2009 55
12 Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma Jonathan Corren, Evelyn Y. Du, Ananda Gubbi et al. · The Journal of Allergy and Clinical Immunology In Practice 28 Oct 2020 41
13 Early Dialogue Between the Developers of New Technologies and Pricing and Reimbursement Agencies: A Pilot Study Martin E. Backhouse, Michael J. Wonder, Edward Hornby et al. · Value in Health Open access Jun 2011 41
14 Antitumor Efficacy of the Novel Chemotherapeutic Agent Coramsine Is Potentiated by Cotreatment With CpG-Containing Oligodeoxynucleotides Robbert van der Most, Robyn P. Himbeck, Simon J. Aarons et al. · Journal of Immunotherapy Mar 2006 29
15 Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab Mark T. Liddament, Jean Husten, Tanya Estephan et al. · Allergy Asthma and Immunology Research Open access 2019 27
16 Clinical Characteristics of People with Heart Failure in Australian General Practice: Results from a Retrospective Cohort Study Andrew Paul Sindone, Deepak Haikerwal, Ralph G. Audehm et al. · ESC Heart Failure Open access 28 Oct 2021 25
17 Evolution of prokaryotic colonisation of greenhouse plastics discarded into the environment Sergio Martínez-Campos, Panayiota Pissaridou, Katerina Drakou et al. · Ecotoxicology and Environmental Safety Open access 24 Jan 2022 21
18 Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose Elpiniki Nikolaou, Eleni Kamilari, Dragana Savkov et al. · World Journal of Pediatrics 3 Oct 2019 21
19 Beneficial Effects of Human Anti-Interleukin-15 Antibody in Gluten-Sensitive Rhesus Macaques with Celiac Disease Karol Sestak, Jason Dufour, David X. Liu et al. · Frontiers in Immunology Open access 11 Jul 2018 21
20 Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study Richard W Simpson, Geoffrey C. Nicholson, Joseph Proietto et al. · Diabetes Care Open access 15 Aug 2014 18
21 Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset Kathleen Tymms, Belinda Butcher, Tracey L. Sletten et al. · Clinical Rheumatology Open access 26 Nov 2021 17
22 Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model Jonathan K. Nambiar, Adam W. Clarke, Doris Shim et al. · mAbs Open access 9 Mar 2015 17
23 Supplementation of Reduced Gluten Barley Diet with Oral Prolyl Endopeptidase Effectively Abrogates Enteropathy-Associated Changes in Gluten-Sensitive Macaques Karol Sestak, Hazel Thwin, Jason Dufour et al. · Nutrients Open access 28 Jun 2016 14
24 Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice ( SUSTAIN study) Peter Anthony Foley, Nicholas Manuelpillai, Con Dolianitis et al. · Australasian Journal of Dermatology Open access 9 Jul 2022 11
25 Consumer opinions on adverse events associated with medicines and vaccines Parisa Aslani, Kim K. Hamrosi, Vivien Tong et al. · Patient Preference and Adherence Open access Jul 2018 11
26 Consumer opinions on adverse events associated with medical devices Parisa Aslani, Kim K. Hamrosi, Vivien Tong et al. · Research in Social and Administrative Pharmacy 21 Jul 2018 9
27 A systematic review of economic evaluations for RPE65-mediated inherited retinal disease including HTA assessment of broader value Maria Farris, Stephen Goodall, Richard De Abreu Lourenço · International Journal of Technology Assessment in Health Care ReviewOpen access 2023 8
28 Interactions between LHX3- and ISL1-family LIM-homeodomain transcription factors are conserved in Caenorhabditis elegans Mugdha Bhati, Estelle Llamosas, David Anthony Jacques et al. · Scientific Reports Open access 28 Jun 2017 8
29 Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study Peter Anthony Foley, Lynda J. Spelman, Dedee Frances Murrell et al. · Australasian Journal of Dermatology Open access 11 Jul 2022 7
30 Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US (4171) Joshua M. Cohen, Stephen Thompson, Oscar Patterson‐Lomba et al. · Neurology 13 Apr 2021 5
31 Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies Zhandong Don Zhong, Lynn L. Jiang, Puneet Khandelwal et al. · The AAPS Journal 29 Jan 2020 5
32 An Oral Iron Chelator and Quality of Life. Richard De Abreu Lourenço, Richard H. Osborne, Andrew Dalton et al. · Blood 16 Nov 2005 5
33 The Dotted Cap Notation: A concise notation for describing variegated dendrimers Benjamin P. Roberts, Martin J. Scanlon, Guy Y. Krippner et al. · New Journal of Chemistry 2008 4
34 Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment (2406) Stephen D. Silberstein, Mario Ortega, Shawn Christopher Elms et al. · Neurology 13 Apr 2021 3
35 Clinical and Economic Outcomes in Patients with Persistent Asthma Who Attain Healthcare Effectiveness and Data Information Set Measures Giselle S Mosnaim, Huan Huang, Rinat Ariely et al. · The Journal of Allergy and Clinical Immunology In Practice Open access 17 Jun 2020 3
36 EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB Katy Bell, Andrew D. Hayen, Paul Glasziou et al. · Retina Open access 19 Aug 2016 3
37 Dorsomedial striatal neuroinflammation causes excessive goal-directed action control by disrupting astrocyte function Arvie Rodriguez Abiero, Joanne M. Gladding, Jacqueline A. Iredale et al. · Neuropsychopharmacology Open access 27 Sep 2025 2
38 Glutamatergic synaptic resilience to overexpressed human alpha-synuclein Patrícia I. Santos, Inés Hojas García-Plaza, Ali Shaib et al. · npj Parkinson s Disease Open access 12 Aug 2025 2
39 Real-World Adherence, Persistence, Switching, and Reinitiation by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices (2145) Krishna Tangirala, Joshua M. Cohen, Shivani Pandya et al. · Neurology 13 Apr 2021 2
40 Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease (P2-11.010) Daniel O. Claassen, Hela Romdhani, Rajeev Ayyagari et al. · Neurology 25 Apr 2023 2
41 No ‘Wearing-Off Effect’ Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use (P12-12.005) Jessica Ailani, Handing Xie, Maurice T. Driessen et al. · Neurology 25 Apr 2023 2
42 Early Collected Leukapheresis Material Improves Tisagenlecleucel Manufacturing Success and Time from Order to Pickup of the Leukapheresis Product: A Real-World Experience Tina Smrekar, Antonio Vendramin, Dominic K. Fernandez et al. · Blood 15 Nov 2022 2
43 Highly adaptable deep-learning platform for automated detection and analysis of vesicle exocytosis Abed Alrahman Chouaib, Hsin‐Fang Chang, Omnia M. Khamis et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 6 Aug 2024 1
44 Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme TA Hardy, Patrick Aouad, Michael Harry Barnett et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical Open access 2024 1
45 Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2–4 Prior Migraine Preventive Medication Classes (2055) Messoud Ashina, Joshua M. Cohen, Maja Galić et al. · Neurology 13 Apr 2021 1
46 Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study (2124) Jonathan P. Gladstone, Hans‐Christoph Diener, Xiaoping Ning et al. · Neurology 13 Apr 2021 1
47 Cardiovascular Safety of Fremanezumab in Patients With Migraine and Cardiovascular Medical History or Risk Factors: A Pooled Analysis of Phase 3 Studies (2382) Stephanie J. Nahas, Tim Patrick Jürgens, Yoel Kessler et al. · Neurology 13 Apr 2021 1
48 US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab (4289) Michael J. Seminerio, Krishna Tangirala, Stephen F. Thompson et al. · Neurology 13 Apr 2021 1
49 Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis (P12-2.002) Maurice T. Driessen, Lynda J. Krasenbaum, Verena Ramirez Campos et al. · Neurology 3 May 2022 1
50 Rationale & Study Design of a Study Based on Implementation Science Guided Principles: A Novel Model of Care for the Management of High Cardiovascular Risk Patients With Elevated Low Density Lipoprotein Cholesterol (LDL-C) in the Australian Primary Care Setting Adam J. Nelson, Alan Herschtal, Julie Butters et al. · Heart Lung and Circulation Open access Jul 2023 1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.